Wang Weiping, Wang Dunhuang, Liu Xiaoliang, Zhou Yuncan, Ma Jiabin, Hou Xiaorong, Hu Ke, Zhang Fuquan
Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
J Cancer. 2020 Jun 28;11(17):5099-5105. doi: 10.7150/jca.45520. eCollection 2020.
Previous studies have shown that prophylactic extended-field irradiation can reduce para-aortic lymph node failure (PALNF) rates in patients with cervical cancer. As such, this type of irradiation may particularly benefit patients with a high risk of PALNF. In the present study, we analyzed the risk factors for PALNF in patients with cervical cancer treated with pelvic irradiation in order to identify potential indications of prophylactic extended-field irradiation. We evaluated patients with 2018 FIGO stage IB3-IIIC1 cervical cancer who were treated with definitive pelvic radiotherapy or concurrent chemoradiotherapy at our institution between 2011 and 2014. Univariate and multivariate analyses were performed to identify risk factors for PALNF. We included 572 patients in the study. The median follow-up period was 37.9 months. Eighteen patients (3.1%) first site of tumor relapse was the para-aortic lymph nodes, and thus showed PALNF. Using multivariate Cox regression analysis, we identified two significant risk factors for PALNF: tumor extension to the pelvic wall (hazard ratio, HR 3.60, p=0.026) and ≥ 2 pelvic MLNs (HR 5.30, p=0.005). For patients with and without risk factors, the 3-year overall survival, disease-free survival, and PALNF rates were 77.3% and 90.1% (p<0.001), 56.4% and 83.1% (p<0.001), and 12.0% and 2.3% (p<0.001), respectively. Tumor extension to the pelvic wall and ≥ 2 pelvic MLNs are positively associated with PALNF after pelvic irradiation in patients with cervical cancer. Further trials will be required to validate whether patients with these two risk factors may benefit from prophylactic extended-field irradiation.
以往研究表明,预防性扩大野照射可降低宫颈癌患者腹主动脉旁淋巴结转移(PALNF)发生率。因此,这类照射可能对PALNF高危患者特别有益。在本研究中,我们分析了接受盆腔照射的宫颈癌患者发生PALNF的危险因素,以确定预防性扩大野照射的潜在适应证。我们评估了2011年至2014年期间在本机构接受根治性盆腔放疗或同步放化疗的2018年国际妇产科联盟(FIGO)IB3-IIIC1期宫颈癌患者。进行单因素和多因素分析以确定PALNF的危险因素。本研究纳入了572例患者。中位随访期为37.9个月。18例患者(3.1%)肿瘤复发的首发部位为腹主动脉旁淋巴结,即发生了PALNF。通过多因素Cox回归分析,我们确定了PALNF的两个显著危险因素:肿瘤侵犯至盆腔壁(风险比,HR 3.60,p=0.026)和≥2个盆腔肿大淋巴结(HR 5.30,p=0.005)。有和没有危险因素的患者,3年总生存率、无病生存率和PALNF发生率分别为77.3%和90.1%(p<0.001)、56.4%和83.1%(p<0.001)以及12.0%和2.3%(p<0.001)。肿瘤侵犯至盆腔壁和≥2个盆腔肿大淋巴结与宫颈癌患者盆腔照射后发生PALNF呈正相关。需要进一步试验来验证具有这两个危险因素的患者是否能从预防性扩大野照射中获益。